NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Cullinan Therapeutics, Inc. (CGEM) Stock Analysis

Cullinan Therapeutics, Inc. (CGEM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CGEM

$14.89

+$0.06 (+0.40%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CGEM with… →

CGEM Key Statistics

As of Oct 21, 2026
Trading
Open
$14.92
Previous Close
$14.83
Day's Range
14.64–15.26
52-Week Range
6.73–23.19
Volume
689.98K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.04
Valuation
Market Cap
$866.56M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.11
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$219.88M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.46M
1-Year Return
+75.59%
Dividend and dates
Earnings Date
November 14, 2026
Avg Volume
875.65K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CGEM closed at $14.89, +75.59% over 1 year.

Cullinan Therapeutics, Inc. (CGEM) has a market capitalization of $866.56M.

In fiscal 2025, CGEM reported revenue of $0.00.

CGEM Stock Return by Calendar Year

Cullinan Therapeutics, Inc. (CGEM) return since Jan 2021: what $10,000 became

1 year
$10,000 $17,559
+75.59%
5 years
$10,000 $6,358
−36.42%
Since Jan 2021
$10,000 $4,978
−50.22%

If you had invested $10,000 in Cullinan Therapeutics, Inc. (CGEM) at the close on January 8, 2021, the earliest close on record here, it would have been worth $4,978 at the close on October 21, 2026: −50.22% in total, −11.36% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+43.86%
2025−15.02%
2024+19.53%
2023−3.41%
2022−31.63%
2021−48.41%

As of October 21, 2026.

CGEM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$219.88M—
2024$0.00−$167.38M—
2023$0.00−$153.16M—
2022$0.00$111.21M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$241.65M−$219.88M—
2024$0.00—−$196.92M−$167.38M—
2023$0.00—−$190.65M−$153.16M—
2022$0.00—−$132.14M$111.21M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Cullinan Therapeutics, Inc. (CGEM) at $866.56M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 109 employees.

The most recent close on file for CGEM is $14.89, dated October 21, 2026. That is +$0.06 (+0.40%) against the previous close. Over the past 52 weeks the price has ranged from $6.73 to $23.19. The latest close sits 121.18% above that 52-week low.

Financial Health

In fiscal 2025, Cullinan Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $219.88M. Earnings per share on a trailing basis come to −3.11.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the total return is +75.59%. Across 5 years the annualized return works out at −8.66%. Beta against the wider market is reported at −0.04. Annualized volatility over the trailing 5 years is 67.24%.

Growth & Income

No dividend is on file for CGEM.

Across the complete calendar years on file, 2024 returned +19.53% and 2021 returned −48.41%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the total return is +43.86%.

Peer Comparison

Cullinan Therapeutics, Inc. (CGEM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cullinan Therapeutics, Inc. CGEM $866.56M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Cullinan Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Visit website →